Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.

Trial Details

NCT ID
NCT04793919
Phase
PHASE2
Sponsor
Associazione Italiana Ematologia Oncologia Pediatrica
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Mylotarg
  • Arsenic Trioxide
  • All-trans retinoic acid
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878
  • Prague, Czechia|50.08804,14.42076
  • Aarhus N, Denmark|56.20367,10.17317
  • Bordeaux, France|44.84124,-0.58046
  • Essen, Germany|51.45657,7.01228

Key Eligibility Criteria

  • Newly diagnosed APL confirmed by the presence of PML/RARα fusion gene
  • Age \<18 years
  • Written informed consent by parents or legal guardians

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →